Eli Lilly and Company (LLY)
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -3.6% change compared to its last close.
3 Reasons Why Lilly (LLY) Is a Great Growth Stock
Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.
3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026
Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.
Eli Lilly's New Drug Data Sets Up a High-Stakes 2026
Since early August, the world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, shares have gained a whopping 71% year-to-date.
Focus: Lilly, Novo lock horns in India's obesity drug race
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.
“History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but there are some caveats
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)
Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices of Zepbound on LillyDirect. But there's much going on in favour of LLY too. 2026 could be good too, which is in line with the company's earlier resilience in the face of price cuts, which the company's outlook would clarify.
Eli Lilly: The Right Long-Term Strategy
Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying competition and looming patent expirations, but is proactively expanding into oral, triple-agonist, and novel biologic modalities to sustain long-term revenue. Valuation risk is high in the near term, yet the robust pipeline support a buy rating for long-term investors.
